CTRI/2017/07/009103招募中4 期
â??Clinical evaluation of efficacy and safety of 3 µg/kg Fentanyl to prevent haemodynamic stress response during laryngoscopy and intubarion in normotensive v/s hypertensive population: A prospective, double blind clinical study.â??
Department of Anaesthesiology Sir T Hospital Bhavnagar0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •NORMOTENSIVE PATIENT:
- •1Age:20 to 50 years
- •2Gender: Male and Female
- •3ASA physical status I and II
- •4Patient posted for elective surgery under general anaesthesia requiring endotracheal intubation
- •5Surgery duration less than two hours
- •6BMI <= 25kg/m2.
- •7Informed written consent for participation in study.
- •8Modified Mallampatti Classification I and II
- •HYPERTENSIVE PATIENT:
- •1Age:20 to 50 years
- •2Gender: Male and Female
- •3ASA physical status II(well controlled primary
- •Idiopathic hypertension (blood pressure <= 140/90) with maximum three antihypertensive
- •medications excluding β blocker)
- •No end organ involvement due to hypertension.
- •4Patient posted for elective surgery under general anaesthesia requiring endotracheal intubation
- •5Surgery duration less than two hours
- •6BMI <= 25kg/m2.
- •7Informed written consent for participation in study.
- •8Modified Mallampatti Classification I and II
排除标准
- •1Patient refusing consent
- •2Patient with Diabetes ,COPD, Renal disease, Cardiac diseases like IHD, Valvular heart disease, AV conduction block, LVF & Psychiatric illness etc.
- •3Patient on drugs likes sedatives, opioids, anti-psychiatrics and β blockers.
- •4ASA physical status III and above.
- •5Anticipated difficult intubation.
- •6BMI 25>=kg/m2
- •7Intubation attempt lasting more than 20seconds
- •8Patient on more than 3 antihypertensive medications.
- •9Defaulter of taking antihypertensive medication as per schedule
研究者
相似试验
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-NLovo Nordisk A/S288
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FIovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-DKovo Nordisk A/S288
已完成
2 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis10019654NL-OMON47918ovo Nordisk12